

Part VI: Summary of the risk management plan

Summary of risk management plan for Paracetamol AGmed 10 mg/ml, solution for infusion

This is a summary of the risk management plan (RMP) for Paracetamol AGmed 10 mg/ml solution for infusion. The RMP details important risks of Paracetamol AGmed 10 mg/ml solution for infusion, how these risks can be minimised, and how more information will be obtained about Paracetamol AGmed 10 mg/ml solution for infusion risks and uncertainties (missing information).

Paracetamol AGmed 10 mg/ml solution for infusion summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Paracetamol AGmed 10 mg/ml solution for infusion should be used.

New safety concerns or changes to the current safety concerns will be included in future updates of Paracetamol AGmed 10 mg/ml solution for infusion RMP.

I. The medicine and what it is used for

Paracetamol AGmed 10 mg/ml solution for infusion is authorised for short-term treatment of moderate pain, especially following surgery and for the short-term treatment of fever, when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible, for complete indication please refer to the SmPC.

It contains paracetamol as the active substance and it is intended for infusion use.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Paracetamol AGmed 10 mg/ml solution for infusion, together with measures to minimise such risks and the proposed studies for learning more about Paracetamol AGmed 10 mg/ml solution for infusion risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, they are supplemented with additional risk minimization measure mentioned under the "summary of risks and missing information" section, below.

In addition to these measures, information about adverse reactions is collected continuously and regularly analyzed, including periodic safety update report (PSUR) assessment, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of Paracetamol AGmed 10 mg/ml solution for infusion are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Paracetamol AGmed 10 mg/ml solution for infusion. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	Medication errors - overdose due to confusion between mL and mg in neonates and overdose in underweight adult patients.
Important potential risks	None
Missing information	None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

Important identified risk: Medication errors - overdose due to confusion between mL and mg in neonates and overdose in underweight adult patients.	
Risk minimisation measures	Routine risk minimisation measures SmPC Section 4.2 (Posology and method of administration) SmPC Section 4.4 (Special Warnings and Precautions for Use) SmPC Section 4.9 (Overdose) Legal status: Available by prescription only PIL Section 3 (How to take AGmed 10 mg/ml solution for infusion) Additional risk minimization measures: - Poster - Dosing Guide Strip

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Paracetamol AGmed 10 mg/ml solution for infusion.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Paracetamol AGmed 10 mg/ml solution for infusion.